Am J Transplant, Volume 20, Suppl 3 Archives - Page 31 of 223 - ATC Abstracts

2020 American Transplant Congress
Incidence of Chronic Kidney Disease after Liver Transplantation Using Measured GFR
N. R. Mazumder¹, J. Levitsky¹, G. Saracino², G. Klintmalm³, J. Trotter², S. Asrani²
¹Gastroenterology and Hepatology, Northwestern University, Chicago, IL, ²Transplant Hepatology, Baylor University Medical Center Dallas, Dallas, TX, ³Transplant Surgery, Baylor University Medical Center Dallas, Dallas, TX
*Purpose: Historical rates of ESRD after LT are 8% (1 year) and 18% (5 years) (Ojo NEJM 2003). However, these rates were based older estimates…
2020 American Transplant Congress
Improving Liver Transplant (LT) Waitlist Attrition
W. Concepcion¹, A. Ahmed¹, Z. Tulu², L. Hogan², A. Bonham¹, A. Gallo¹, M. Melcher¹, P. Kwo¹, C. Esquivel¹
¹Stanford University Medical Center, Palo Alto, CA, ²Stanford Health Care, Palo Alto, CA
*Purpose: LT patients are listed with the goal of receiving a transplant. Jan-2018 SRTR report showed that our observed waitlist (WL) mortality rate was 11.8…
2020 American Transplant Congress
Outcomes of Simultaneous Pancreas and Kidney Transplantation Based on Donor Resuscitation
F. Messner¹, J. W. Etra², Y. Yu³, K. Jackson², A. B. Massie², G. Brandacher², S. Schneeberger⁴, C. Margreiter⁴, D. L. Segev²
¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD, ⁴Department of Visceral, Transplant and Thoracic Surgery, Medical University of Innsbruck, Innsbruck, Austria
*Purpose: It has been hypothesized that transplanting simultaneous pancreas kidney (SPK) grafts from donors with a history of cardiac arrest and cardiopulmonary resuscitation (CACPR) leads…
2020 American Transplant Congress
Accelerated Bronchiolitis Obliterans after Lung Transplant Promoted by the ATG16L1 rs2241880 Mutation is Coupled to Mitochondrial Damage and Metabolic Alterations in Monocyte-Derived Alveolar Macrophages
M. Cano¹, D. Zhou², D. Kreisel³, C. Chen⁴, K. Pugh², D. Byers¹, R. Hachem¹, A. E. Gelman³
¹Pulmonary and Critical Care, Washington University, Saint Louis, MO, ²Surgery, Washington University, Saint Louis, MO, ³Surgery and Pathology and Immunology, Washington University, Saint Louis, MO, ⁴Pulmonary and Critical Care, Southwestern Medical Center, Dallas, TX
*Purpose: Bronchiolitis obliterans (BOS) remains a major cause of death for lung transplant recipients, and the mechanisms that drive BOS remain poorly understood and require…
2020 American Transplant Congress
Using Trajectory Analysis to Characterize Trends in OPO Performance with Population-Based Metrics
K. Ross¹, D. Goldberg², R. Lynch¹
¹Emory University, Emory Transplant Center, Atlanta, GA, ²University of Miami, Miami, FL
*Purpose: Identifying the organ procurement organizations (OPOs) with the greatest opportunity to improve donation rates may help increase the number of transplants in the United…
2020 American Transplant Congress
Analysis of 1000 Protocol Kidney Biopsies: Complications, Benefits, and Predictive Potential of Prior Sensitization
M. Eslami¹, J. Patel², S. Karzai¹, D. T. Collins¹, C. Liu¹, J. Jonsson¹, R. Wali¹, J. B. Piper¹
¹Surgery, Inova Fairfax Hospital, Falls Church, VA, ²General Surgery, Pennsylvania State University, State College, PA
*Purpose: Protocol biopsy of kidney transplants can allow for early recognition of treatable findings, both immunologic and non-immunologic. This comes with the risk of biopsy…
2020 American Transplant Congress
Plasma Microbiome Profiles of Liver Transplant Patients with Operational Tolerance
C. Kuscu¹, J. Pierre², I. Lies¹, C. Kuscu¹, A. Bajwa¹, A. Wolen¹, J. Eason¹, B. Ramaswami³, D. Maluf¹, G. Mazariegos³, G. Chalasani³, V. Mas¹
¹James D. Eason Transplant Institute, Department of Surgery, UTHSC, Memphis, TN, ²Department of Pediatrics, UTHSC, Memphis, TN, ³Thomas E. Starzl Transplantation Institute, Children's Hospital of Pittsburgh, UPMC, Pittsburgh, PA
*Purpose: Microbiome has emerged as a key modulator of organ homeostasis and immune system function with altered microbiota and microbiome - host interactions contributing to…
2020 American Transplant Congress
Socio-Demographic Disparities in Access to Organs from HCV-Viremic Donors among HCV-Negative Patients
T. Nguyen¹, W. Williams², M. Sise², P. Reese³, D. Goldberg¹
¹Medicine, University of Miami, Miami, FL, ²Massachusetts General Hospital, Boston, MA, ³University of Pennsylvania, Philadelphia, PA
*Purpose: The success of pilot trials of transplanting organs from hepatitis C virus (HCV) viremic donors into HCV-negative recipients (HCV D+/R-) has led to an…
2020 American Transplant Congress
Long-Term Outcomes of Patients with Epstein-barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Solid Organ Transplant or Allogeneic Hematopoietic Cell Transplant Treated with Tabelecleucel in an Expanded Access Program Study
S. Prockop¹, R. Reshaf², D. Tsai³, N. Bunin⁴, R. Abu-Arja⁵, K. Mahadeo⁶, W. Weng⁷, K. Van Besien⁸, D. Loeb⁹, S. Dwivedy Nasta¹⁰, E. Nemecek¹¹, M. Hiremath¹², S. Yue¹², Y. Sun¹², W. Navarro¹², S. Nikiforow¹³
¹Memorial Sloan Kettering Cancer Center, New York, NY, ²Columbia University Irving Medical Center, New York, NY, ³Loxo Oncology, Stamford, CT, ⁴The Children's Hospital of Philadelphia, Philadelphia, PA, ⁵Nationwide Children's Hospital, Columbus, OH, ⁶MD Anderson Cancer Center, Houston, TX, ⁷Stanford University School of Medicine, California, CA, ⁸Weill Cornell Medical College, New York, NY, ⁹Children's Hospital at Montefiore, Bronx, NY, ¹⁰University of Pennsylvania, Philadelphia, PA, ¹¹Oregon Health & Science University, Portland, OR, ¹²Atara Biotherapeutics, New York, NY, ¹³Dana Farber Cancer Institute, Boston, MA
*Purpose: There is a need for effective, well‑tolerated therapies in pts who develop Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) after solid organ (SOT) or…
2020 American Transplant Congress
Long-Term Outcomes with Islet Alone and Islet-after-Kidney Transplantation for Type 1 Diabetes in the Clinical Islet Transplantation Consortium
M. R. Rickels¹, T. L. Eggerman², L. Bayman³, J. C. Qidwai³, R. Alejandro⁴, N. D. Bridges⁵, B. J. Hering⁶, J. F. Markmann⁷, P. A. Senior⁸, L. G. Hunsicker³
¹Institute for Diabetes, Obesity & Metabolism, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ²National Institute of Diabetes and Digestive and Kidney Disease, Bethesda, MD, ³University of Iowa, Iowa City, IA, ⁴University of Miami, Miami, FL, ⁵National Institute of Allergy and Infectious Disease, Bethesda, MD, ⁶University of Minnesota, Minneapolis, MN, ⁷Massachusetts General Hospital, Boston, MA, ⁸University of Alberta, Edmonton, AB, Canada
*Purpose: Phase 3 studies of islet transplant alone (ITA; n=48) and islet-after-kidney (IAK; n=24) transplantation in type 1 diabetes complicated by severe hypoglycemic events (SHE)…